As our exploration of the NGS landscape deepens using our NGS DxBook, we're unveiling nuances that redefine our understanding of centralized vs. in-house clinical NGS testing dynamics.
This week, we focus on the patterns of NGS in-house testing vs. outsoucing in relation to hospital size. Interestingly, the commitment to in-house testing isn’t just the prerogative of larger institutions; even smaller labs show considerable dedication once they integrate NGS, typically reserving outsourcing for larger panels or hereditary cancer testing.
Based on our recent analysis / Linkedin carousels, the transformative potential of NGS in oncology care is increasingly evident. This week’s data uncovers another layer: the willingness to in-source routine testing once volume exceed ~1,250 tests / year (i.e., ~25 / week). With centralized NGS providers serving a dual market and in-house labs showing remarkable commitment, the NGS domain is in flux. One thing remains clear: as labs expand their capabilities, the momentum towards more personalized and effective treatments becomes even more pronounced.
Swipe to dive into the rich insights of this week’s analysis! And reach out to Rishikesh to learn more!
#NGSisUnstoppable
.png)
.png)
